CYTOKINETICS, INCORPORATED Unrecognized Tax Benefits that Would Impact Effective Tax Rate
CYTOKINETICS, INCORPORATED (CYTK) had Unrecognized Tax Benefits that Would Impact Effective Tax Rate of $30.20 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate · last filed 2025-02-27
- 2024-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $30.20M.
- 2023-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $24.50M.
- 2022-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $17.70M.
- 2021-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $10.30M.
| Period end | Unrecognized Tax Benefits that Would Impact Effective Tax Rate |
|---|---|
| 2024-12-31 | $30.20M 10-K · filed 2025-02-27 |
| 2023-12-31 | $24.50M 10-K · filed 2025-02-27 |
| 2022-12-31 | $17.70M 10-K · filed 2025-02-27 |
| 2021-12-31 | $10.30M 10-K · filed 2024-02-28 |
| 2020-12-31 | $9.60M 10-K · filed 2023-03-01 |
| 2019-12-31 | $9.10M 10-K · filed 2022-02-25 |
| 2018-12-31 | $8.60M 10-K · filed 2021-02-26 |
| 2017-12-31 | $8.10M 10-K · filed 2019-03-07 |
| 2016-12-31 | $6.30M 10-K · filed 2018-03-05 |
| 2015-12-31 | $5.50M 10-K · filed 2018-03-05 |
| 2014-12-31 | $5.10M 10-K · filed 2017-03-06 |
| 2013-12-31 | $5.00M 10-K · filed 2016-03-03 |
| 2012-12-31 | $4.20M 10-K · filed 2015-03-06 |
| 2011-12-31 | $4.30M 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |